SB 80 — AN ACT CONCERNING THE SHORTAGE OF CERTAIN DRUGS PRESCRIBED TO TREAT TYPE II DIABETES.

Senate General Assembly CommitteeFile Bill No.

8094 January Session, 2023 LCOSenate Bill No.

507080 ReferredSenate, toMarch 16, 2023 The Committee on GENERALGeneral LAWLaw Introducedreported by:through SEN.

(GL)MARONEY ANof ACTthe CONCERNING14th THEDist., SHORTAGEChairperson OFof CERTAINthe DRUGSCommittee PRESCRIBEDon TOthe TREATpart TYPEof IIthe DIABETES.Senate, that the bill ought to pass.

AN ACT CONCERNING THE SHORTAGE OF CERTAIN DRUGS PRESCRIBED TO TREAT TYPE II DIABETES.

SectionSB80 1/ fromFile passage New section LCO 5070 \\PRDFS1\SCOUSERS\FORZANOF\WS\2023SB-00080-R01 of 2 SB.docx Committee Bill No.

8094 GL1 JointSB80 FavorableFile LCONo. 5070 {\\PRDFS1\SCOUSERS\FORZANOF\WS\2023SB-00080- 2 of 2 R02-SB.docx }

94 Section 1 from passage New section GL Joint Favorable SB80 / File No.

94 2 SB80 File No.

94 The following Fiscal Impact Statement and Bill Analysis are prepared for the benefit of the members of the General Assembly, solely for purposes of information, summarization and explanation and do not represent the intent of the General Assembly or either chamber thereof for any purpose.

In general, fiscal impacts are based upon a variety of informational sources, including the analyst’s professional knowledge.

Whenever applicable, agency data is consulted as part of the analysis, however final products do not necessarily reflect an assessment from any specific department.

OFA Fiscal Note State Impact:

None Municipal Impact:

None Explanation The bill requires the Commissioner of Consumer Protection to adopt regulations regarding certain drugs that treat type II diabetes resulting in no fiscal impact to the state because the agency has the expertise to meet the requirements of the bill.

The Out Years State Impact:

None Municipal Impact:

None SB80 / File No.

94 3 SB80 File No.

94 OLR Bill Analysis SB 80 AN ACT CONCERNING THE SHORTAGE OF CERTAIN DRUGS PRESCRIBED TO TREAT TYPE II DIABETES.

SUMMARY This bill requires the consumer protection commissioner to adopt regulations to ensure that there is a sufficient supply of dulaglutide and semaglutide to treat patients in the state with type II diabetes.

The bill specifies that the regulations may, among other things, prohibit pharmacists from dispensing these medications off-label while the drug is in short supply in Connecticut (see BACKGROUND).

EFFECTIVE DATE:

Upon passage BACKGROUND Dulaglutide and Semaglutide Supply Shortage Certain of these drugs, which are approved by the FDA for type II diabetes treatment, are currently included on the FDA’s Drug Shortages list.

Global demand for this class of drugs rose after clinical trials showed they provide weight loss benefits when prescribed off-label to non-diabetic patients.

COMMITTEE ACTION General Law Committee Joint Favorable Yea 23 Nay 0 (03/02/2023) SB80 / File No.

94 4